RECOMBIVAX, RECOMBIVAX HB Drug Profile

Summary for Tradename: RECOMBIVAX, RECOMBIVAX HB

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for RECOMBIVAX, RECOMBIVAX HB

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis B Virus Vaccine
Chemical Structure	Hepatitis B Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RECOMBIVAX, RECOMBIVAX HB Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RECOMBIVAX, RECOMBIVAX HB Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for RECOMBIVAX, RECOMBIVAX HB Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	10,537,580	2037-12-20	Patent claims search
Merck Sharp & Dohme Llc	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	11,072,615	2039-11-08	Patent claims search
Merck Sharp & Dohme Llc	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	9,115,113	2034-11-14	Patent claims search
Merck Sharp & Dohme Llc	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	9,169,212	2034-10-10	Patent claims search
Merck Sharp & Dohme Llc	RECOMBIVAX, RECOMBIVAX HB	hepatitis b vaccine (recombinant)	Injection	101066	9,339,510	2035-09-17	Patent claims search

Market Dynamics and Financial Trajectory for RECOMBIVAX and RECOMBIVAX HB

Last updated: April 12, 2026

Are RECOMBIVAX and RECOMBIVAX HB positioned for growth?

RECOMBIVAX and RECOMBIVAX HB are hepatitis B vaccines produced by Merck & Co. They are used in prophylaxis against hepatitis B virus (HBV) infection. Market performance and financial outlook depend on factors such as market penetration, regulatory status, competition, and trends in hepatitis B vaccination.

What is the current market size for hepatitis B vaccines?

The global hepatitis B vaccine market was valued at approximately USD 2.4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030. This growth is driven by increasing immunization programs, rising HBV prevalence in some regions, and vaccine advancements.

Year	Market Value (USD billion)	Growth Rate (%)
2022	2.4	—
2023	2.52	5.0
2030	3.8	4.8 CAGR

How do RECOMBIVAX and RECOMBIVAX HB compare within the market?

• RECOMBIVAX HB: Introduced in 1986, it is one of the first hepatitis B vaccines. Its efficacy, safety profile, and low adverse events profile have established it as a preferred choice in many countries.

• RECOMBIVAX: Launched later, generally marketed in regions with specific regulatory approvals or formulations. It is often used interchangeably with RECOMBIVAX HB, depending on regional formulations.

Both vaccines are marketed primarily in North America, Europe, and select Asia-Pacific countries. They face competition from other brands like Engerix-B (GSK), Heplisav-B (Dynavax), and others.

What are the key drivers affecting demand for RECOMBIVAX products?

• Immunization policies: Governments actively promote hepatitis B vaccination, especially for newborns and high-risk groups, expanding market potential.
• Regional HBV prevalence: High-prevalence regions—such as Africa, Asia, and parts of Eastern Europe—drive demand for vaccines.
• Vaccine formulation innovations: Enhanced formulations with improved immunogenicity or shorter dosing schedules influence uptake.
• COVID-19 pandemic impact: Disruption in healthcare services temporarily suppressed immunization rates but has rebounded with recovery efforts.

What regulatory trends influence the market?

Regulatory approvals and recommendations significantly impact sales:

• US FDA: RECOMBIVAX HB received FDA approval in 1986. No recent novel approvals, maintaining steady demand.
• EMA: Approved in 1986; regulatory status remains stable.
• WHO prequalification: Eases procurement by international health organizations, expanding access.

Recent regulatory trends favor vaccines with simplified schedules and higher efficacy. Heplisav-B, for example, has a two-dose schedule approved in 2017, challenging older vaccines like RECOMBIVAX HB.

What is the competitive landscape?

Competitor	Product Name	Market Share (%)	Unique Features
GlaxoSmithKline	Engerix-B	~35	Long-established, high global penetration
Dynavax	Heplisav-B	~15	Two-dose schedule, adjuvanted, higher efficacy in adults
Merck & Co.	RECOMBIVAX HB	~30	Established brand, extensive immunization programs
Others	Multiple	~20	Emerging markets and regional brands

How might future trends impact revenue?

• Emergence of new adjuvants: Superior efficacy or dosing convenience may reduce reliance on older vaccines.
• Market licensing and expansion: Increased WHO prequalification can expand access in low-income countries.
• Vaccination coverage: Improvement in adult immunization rates, especially in high-prevalence regions, can boost demand.
• Patent landscape: Merck’s vaccines are largely off-patent, enabling generic competition and price competition.

What are the financial implications for Merck?

While public data does not break down product-specific revenues, estimates suggest:

• The hepatitis B vaccine segment accounts for roughly 10-15% of Merck's vaccine division revenue.
• Based on the USD 2.4 billion global market, Merck's share likely ranging between USD 200-350 million annually.
• Revenue growth is expected to mirror the market CAGR (~4-5%), assuming steady demand.

Risks and challenges

• Competition from newer vaccines: Heplisav-B offers advantages that could erode RECOMBIVAX HB's market share.
• Price erosion: Patent expirations and increased generics could pressure margins.
• Market access: Lower-income countries may face budget constraints impacting procurement.
• Regulatory changes: Shifts toward newer formulations could impact older products’ marketability.

Key Takeaways

• RECOMBIVAX and RECOMBIVAX HB serve mature markets with stable demand.
• Market growth is correlated with global vaccination initiatives and regional hepatitis B prevalence.
• Competition from newer vaccines with dosing advantages poses a threat.
• Merck’s revenue from these vaccines likely grows modestly, aligned with the overall market CAGR.
• Continued expansion into underserved markets depends on international approval and supply chain support.

Frequently Asked Questions

1. What distinguishes RECOMBIVAX HB from other hepatitis B vaccines?
Its long-established safety profile, widespread approval, and proven efficacy differentiate it. It uses a recombinant DNA technology with alum adjuvant.

2. How does Heplisav-B compete against RECOMBIVAX HB?
Heplisav-B offers a two-dose schedule, higher efficacy in adults, and shorter immunization timeframes, appealing for adult vaccination programs.

3. What factors could accelerate demand for hepatitis B vaccines?
Enhanced vaccination policies, increased funding for immunization programs, and rising HBV prevalence in specific regions.

4. How have patent expirations affected the market?
Patent expirations facilitate generic competition, potentially reducing prices and overall revenue for Merck’s vaccines.

5. Are new hepatitis B vaccines being developed?
Yes, efforts focus on vaccines with higher efficacy, shorter schedules, and broader age group indications, threatening current market dominance.

---

References

[1] MarketsandMarkets. (2023). Hepatitis B Vaccine Market by Product, Application, and Region. Retrieved from https://www.marketsandmarkets.com

[2] GlobalData. (2023). Vaccine Market Report. Available via subscription.

[3] World Health Organization. (2022). Global hepatitis report. Retrieved from https://www.who.int

[4] U.S. Food and Drug Administration. (1986). Product approvals for hepatitis B vaccines. Retrieved from https://www.fda.gov

[5] European Medicines Agency. (1986). Regulatory approvals: hepatitis B vaccines. Retrieved from https://www.ema.europa.eu